Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Описание к видео Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center discusses patient selection and the treatment landscape in metastatic hormone-sensitive prostate cancer (mHSPC). Dr. McKay assesses three overarching factors, disease, clinical, and drug, that impact treatment decisions and how to optimize them.

Комментарии

Информация по комментариям в разработке